

10-27-05

IFW

Express Mail Label  
No. EV619622621US

Attorney Docket No.: VOS-48



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Mohammed Shahid  
Application No. : 10/783,821 Confirmation No. : 7055  
Filed : February 20, 2004  
For : SYNTHESIS OF SOLANUM GLYCOSIDES  
Group Art Unit : 1614  
Examiner : Not yet assigned

New York, New York 10020  
October 25, 2005

Mail Stop AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicant hereby makes the following publications of record in the above-identified patent application:

OTHER DOCUMENTS

Cham, B.E., et al., "Topical treatment of malignant and premalignant skin lesions by very low concentrations of a standard mixture (BEC) of solasodine glycosides", Cancer Letters, Vol. 59, 1991, pp. 183-192.

Drugs of the Future, "BEC", Vol. 13, 8, 1988, pp. 714-716.

Cham, B.E., et al., "Topical treatment of pre-malignant and malignant skin cancers with curaderm", Drugs of Today, Vol. 26, No. 1, 1990, pp. 55-58.


Copies of the aforementioned publications, which are listed on the accompanying Form SB/08 (submitted in duplicate), are enclosed herewith.

It is respectfully requested that these publications be (1) fully considered by the Patent and Trademark Office during examination of this application; and (2) printed on any patent which may issue on this application. Applicant requests that a copy of Form SB/08, as considered and initialed by the Examiner, be returned with the next communication.

This Information Disclosure Statement is being submitted before the mailing of a first Office Action on the merits. In accordance with 37 C.F.R. § 1.97(b)(1), submission of this Statement requires no fee. However, if for any reason a fee is due, the Director is hereby authorized to charge payment of any fees required in connection with this Information Disclosure Statement to Deposit Account No. 06-1075 (Order No. 003747-0088).

An early and favorable action is respectfully requested.

Respectfully submitted,



James F. Haley, Jr. (Reg. No. 27,794)  
Attorney for Applicant

FISH & NEAVE IP GROUP  
ROPES & GRAY LLP  
Customer No. 1473

1251 Avenue of the Americas  
New York, New York 10020-1105  
Tel.: (212) 596-9000  
Fax.: (212) 596-9090



Attorney Docket No.: VOS-48

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Mohammed Shahid  
Application No. : 10/783,821 Confirmation No. : 7055  
Filed : February 20, 2004  
For : SYNTHESIS OF SOLANUM GLYCOSIDES  
Group Art Unit : 1614  
Examiner : Not yet assigned

New York, New York 10020  
October 25, 2005

Mail Stop AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

EXPRESS MAIL CERTIFICATION

“Express Mail” mailing label number EV619622621US  
Date of Deposit October 25, 2005

I hereby certify that this paper/fee is being deposited with the United States Postal Service “EXPRESS MAIL POST OFFICE TO ADDRESSEE” service under 37 C.F.R. 1.10 on the date indicated above and is addressed to Mail Stop AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

  
Name: Isatta B. Smith

Encl:

- Information Disclosure Statement (in duplicate);
- Form SB/08 (in duplicate);
- Copies of three (3) cited references; and
- Return postcard.



Express Mail Label No. EV619622621US

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)  Sheet 1 of 1				<b>Complete if known</b>	
				Application Number	10/783,821
				Filing Date	February 20, 2004
				First Named Inventor	Mohammed Shahid
				Art Unit	1614
				Examiner Name	Not yet assigned
				Attorney Docket Number	VOS-48

U.S. PATENT DOCUMENTS					
Examiner initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>1</sup> - Number <sup>2</sup> - Kind Code <sup>3</sup>				

NON PATENT LITERATURE DOCUMENTS			
Examiner initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>6</sup>
		Cham, B.E., et al., "Topical treatment of malignant and premalignant skin lesions by very low concentrations of a standard mixture (BEC) of solasodine glycosides", <u>Cancer Letters</u> , Vol. 59, 1991, pp. 183-192.	
		<u>Drugs of the Future</u> , "BEC", Vol. 13, 8, 1988, pp. 714-716.	
		Cham, B.E., et al., "Topical treatment of pre-malignant and malignant skin cancers with curaderm", <u>Drugs of Today</u> , Vol. 26, No. 1, 1990, pp. 55-58.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

All References Have Been Considered:

Examiner

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.